Platform Infrastructure for Agile Software Estimation

Symposium PresentationApproved for public release; distribution is unlimited

Platform Infrastructure for Agile Software Estimation

Excerpt from the Proceedings of the Nineteenth Annual Acquisition Research SymposiumSoftware acquisition reform is a hot topic in the DoD, but the oversight community is struggling to adapt to changes. I diagnose some issues with the current state of business in the Software Acquisition Pathway and propose a system called Overlord to increase the level of automation in software program management and oversight. My goal is to make life easier for software developers, program managers, and members of the oversight community.Approved for public release; distribution is unlimited

Platform Infrastructure for Agile Software Estimation

Excerpt from the Proceedings of the Nineteenth Annual Acquisition Research SymposiumSoftware acquisition reform is a hot topic in the DoD, but the oversight community is struggling to adapt to changes. I diagnose some issues with the current state of business in the Software Acquisition Pathway and propose a system called Overlord to increase the level of automation in software program management and oversight. My goal is to make life easier for software developers, program managers, and members of the oversight community.Approved for public release; distribution is unlimited

TVA’s Brief in Reply to Plaintiffs’ Post-Trial Brief, \u3cem\u3eTVA v. Hill et al\u3c/em\u3e, Civil Action No. 3-76-48

Brief for the defendants in response to the plaintiffs\u27 post-trial brief in the case of TVA v. Hill et al in the United States District Court for the Eastern District of Tennessee, Northern Division

Post-Trial Brief of Tennessee Valley Authority, \u3cem\u3eTVA v. Hill et al\u3c/em\u3e, Civil Action No. 3-76-48

Post-trial brief for the defendants in the case of TVA v. Hill et al in the United States District Court for the Eastern District of Tennessee, Northern Division

Trial Brief of TVA, \u3cem\u3eTVA v. Hill et al\u3c/em\u3e, Civil Action No. 3-76-48

Brief for the defendants in the case of TVA v. Hill et al in the United States District Court for the Eastern District of Tennessee, Northern Divisio

Petition for a Writ of Certiorari to the United States Court of Appeals for the Sixth Circuit, \u3cem\u3eTVA v. Hill\u3c/em\u3e, No. 76-1701

Petition requesting that the United States Supreme Court hear an appeal to the decision of the United States Court of Appeals for the Sixth Circuit in Tennessee Valley Authority v. Hiram G. Hill Jr., et al.

Reply Brief for the Petitioner, \u3cem\u3eTVA v. Hill\u3c/em\u3e, No. 76-1701

Reply brief for the petitioner in the case of Tennessee Valley Authority v. Hiram G. Hill Jr., et al., heard by the United States Supreme Court in the October Term of 1977

Brief for the Petitioner, \u3cem\u3eTVA v. Hill\u3c/em\u3e, No. 76-1701

Brief for the petitioner in the case of Tennessee Valley Authority v. Hiram G. Hill Jr., et al., heard by the United States Supreme Court in the October Term of 1977

Leading change in academic pharmacy: Report of the 2018-2019 aacp academic affairs committee

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. Delivering an effective drug load to the posterior section of the ocular tissues, while using a non-invasive technique, has always been a challenge. In this regard, the goal of the present study was to develop sustained release triamcinolone acetonide (TA) loaded polymeric matrix films for ocular delivery. The TA-films were prepared in two different polymer matrices, with drug loadings of 10% and 20% w/w, and they were evaluated for ocular distribution in vivo in a conscious rabbit model. A 4% w/v TA suspension (TA-C) was used as a control for in vitro and in vivo studies. The TA-films, prepared with melt-cast technology, used polyethylene oxide (PEO) and Soluplus® as the polymer matrix. The films were evaluated with respect to assay, content uniformity, excipient interaction, and permeability across isolated rabbit sclera. The distribution of TA in the ocular tissues, post topical administration, was determined in New Zealand male albino rabbits as a function of dose, and was compared against TA-C. The assay of the 10% and 20% w/w film was in the range from 70–79% and 92–94% for the Soluplus® and PEO films, respectively, and content uniformity was in the range of 95–103% for both the films. The assay of the TA from Soluplus® films was less compared with the PEO films and showed an interaction with TA, as revealed by Differential Scanning Calorimetry (DSC). Hence, Soluplus® films were not selected for further studies. No interaction was observed between the drug and PEO polymer matrix. The enhancement of trans-scleral flux and permeability of TA was about 1.16 and 1.33-folds, respectively, from the 10% w/w PEO and 3.5 and 2.12-folds, respectively, from the 20% w/w PEO films, as compared with TA-C formulations. The in vivo studies demonstrate that significantly higher TA levels were observed in the anterior and posterior segments of the eye at the end of 6h with the PEO films. Therefore, the PEO based polymeric films were able to deliver TA into the back of the eye efficiently and for prolonged periods. View Full-Tex